Skip to main content
. 2015 Mar 19;10:2229–2248. doi: 10.2147/IJN.S79840

Table 1.

The characterization of DOX-LTSL-CREKA (n=3)

Formulation Size (nm) PDI Zeta potential (mV) Entrapment efficiency (%)
DOX-LTSL 85.6±2.7 0.18±0.03 −3.67±0.09 98.98±0.66
DOX-LTSL-CREKA 83.8±3.4 0.19±0.03 −5.96±0.09 99.03±0.63

Abbreviations: DOX, doxorubicin; LTSL, lysolipid-containing thermosensitive liposome; CREKA, Cys-Arg-Glu-Lys-Ala; PDI, polydispersity index.